TRANSCODE THERAPEUTICS, INC.
  • Home
  • About
    • Who We Are
    • Leadership
    • Partnering
  • Focus
  • Science
  • Pipeline
    • Platform
    • TTX-MC138
    • Other Candidates
  • Resources
  • Investors
  • Careers

Leadership

Leadership

TransCode's senior leadership team combines decades of oncology drug discovery and development expertise, life science business acumen and Wall Street knowledge to add both scientific insight and valuable strategic perspective to address cancer and create a sustainable commercialization product pipeline. Our scientists have decades of experience in the foundational areas of RNA and drug development, employing a variety of RNA approaches based on cancer indication and patient needs.

Executive Team

Picture
​Michael Dudley
Founder, President & CEO
Picture
Tom Fitzgerald, MBA
CFO, VP of Administration
Picture
Susan Duggan, RN, MBA
VP of Clinical Operations
Picture
Dustan Bonnin, CVA, MBA
VP of Corporate Strategy
Picture
Alan Freidman
​VP of Investor Relations
Picture
Zdravka Medarova, PhD
Founder/Chief Technology Officer
Picture
Peter Liu, PhD
VP R&D and ​Chief Scientist
Picture
Eric Wesoloski
​Sr. Director Quality
Picture
Subrata Ghosh, PhD
​Principal Scientist
Picture
Ram Bhat, PhD
​Sr. Director CMC

Board of Directors

Picture
Philippe Calais, PhD
​Board Chair
Picture
Magda Marquet, PhD
​Director
Picture
Erik Manting, PhD
​Director
Picture
Michael Dudley, President, CEO and Director
Picture
CFO, VP of Administration Director

Advisory Board

Picture
Anna Moore, PhD
​Founder
Picture
Keith Flaherty, MD
Picture
Raghu Kalluri, MD, PhD
Picture
George Calin, MD, PhD
Picture
Dejan Juric, MD

Picture
Dmitry Samarsky
​PhD
Picture
G. Susan Srivatsa
​PhD
Picture
Raul Mostoslavsky
​MD, PhD
Picture
Lubomir Nechev
​PhD
Picture
Frank J.Slack
​PhD

Picture
Mehmet Yigit
​PhD
Picture
Betsabeh Madani Hermann
​MBA​, MENG
Picture
Jerome Lewis
​PhD, MBA
Picture
John Henneman III
​JD
Picture
Oliver Steinbach
​PhD
TTX is an investigational platform encompassing therapeutic candidates (including TTX-MC138) and diagnostics which remain in development. Their safety and efficacy have not yet been evaluated by the FDA or any other regulatory agency.

Home

About

About
leadership

Partnering
​Careers     

Focus

Focus

Science

Science
​Resources

Pipeline

PIPELINE
TTX-MC138
​OTHER CANDIDATES

Contact/Support

Contact
​TERMS OF USE
PRIVACY POLICY
FCOI Policy
​
© TRANSCODE THERAPEUTICS, INC. 2022.​ ALL RIGHTS RESERVED.
  • Home
  • About
    • Who We Are
    • Leadership
    • Partnering
  • Focus
  • Science
  • Pipeline
    • Platform
    • TTX-MC138
    • Other Candidates
  • Resources
  • Investors
  • Careers